Tuberculosis
Conditions
Interventions
Sponsors
Stellenbosch University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. children aged between eight and seventeen years of age who are routinely treated with intramuscular amikacin as part of their drug-resistant TB regimen 2. children receiving intramuscular amikacin for at least fourteen days but less than eight weeks at enrolment
Exclusion criteria
Exclusion criteria: 1. Informed consent and/or assent not obtained 2. Acute illness 3. Significant neurological impairment 4. Haemoglobin of less than 8g/dl 5. Weight less than 10kg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in pain intensity achieved when lignocaine is co-administered with intramuscular injection of amikacin, as measured by the FACES pain scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Local or systemic adverse effects occurring when lignocaine is administered together with amikacin in an intramuscular injection;The bioavailability of amikacin when co-administered with lignocaine as an intramuscular injection | — |
Countries
South Africa
Contacts
Public ContactAnthony Garcia-Prats
Research Clinician
Outcome results
None listed